Knockdown of DEAD-box RNA helicase 52 (DDX52) suppresses the proliferation of melanoma cells in vitro and of nude mouse xenografts by targeting c-Myc

References

• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392:971–984.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Bertinato L, Staniszewska M, et al. From conventional therapies to immunotherapy: melanoma treatment in review. Cancers. 2020;12.
   PubMed Web of Science ®Google Scholar
• Linder P, Jankowsky E. From unwinding to clamping - the DEAD box RNA helicase family. Nat Rev Mol Cell Biol. 2011;12:505–516.
   PubMed Web of Science ®Google Scholar
• Heerma van Voss MR, van Diest PJ, Raman V. Targeting RNA helicases in cancer: the translation trap, Biochimica et biophysica acta. Rev Cancer. 2017;1868:510–520.
   Google Scholar
• Taschuk F, Cherry S. DEAD-box helicases: sensors, regulators, and effectors for antiviral defense. Viruses. 2020;12(2):181.
   PubMed Web of Science ®Google Scholar
• Li Q, Yang H, He L, et al. Characterization of the Es-DDX52 involved in the spermatogonial mitosis and spermatid differentiation in Chinese mitten crab (Eriocheir sinensis). Gene. 2018;646:106–119.
   PubMed Web of Science ®Google Scholar
• Xing C, Tian H, Zhang Y, et al. DDX39 overexpression predicts a poor prognosis and promotes aggressiveness of melanoma by cooperating with SNAIL. Front Oncol. 2020;10:1261.
   PubMed Web of Science ®Google Scholar
• Bhattacharya C, Wang X, Becker D. The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas. Mol Cancer. 2012;11:82.
   PubMed Web of Science ®Google Scholar
• Santoriello C, Sporrij A, Yang S, et al. RNA helicase DDX21 mediates nucleotide stress responses in neural crest and melanoma cells. Nat Cell Biol. 2020;22:372–379.
   PubMed Web of Science ®Google Scholar
• Johansson JA, Marie KL, Lu Y, et al. PRL3-DDX21 transcriptional control of endolysosomal genes restricts melanocyte stem cell differentiation. Dev Cell. 2020;54:317–332.e319.
   PubMed Web of Science ®Google Scholar
• Ying SY, Lin SL. Gene expression in precursor cells of prostate cancer associated with activin by combination of subtractive hybridization and microarray technologies. Biochem Biophys Res Commun. 2004;313:104–109.
   PubMed Web of Science ®Google Scholar
• Lin L, Chamberlain L, Pak ML, et al. A large-scale RNAi-based mouse tumorigenesis screen identifies new lung cancer tumor suppressors that repress FGFR signaling. Cancer Discov. 2014;4:1168–1181.
   PubMed Web of Science ®Google Scholar
• Liu J, Luan W, Zhang Y, et al. HDAC6 interacts with PTPN1 to enhance melanoma cells progression. Biochem Biophys Res Commun. 2018;495:2630–2636.
   PubMed Web of Science ®Google Scholar
• Wang Q, Peng R, Wang B, et al. Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells. Cancer Biomark. 2018;22:533–541.
   PubMed Web of Science ®Google Scholar
• Jamerson MH, Johnson MD, Dickson RB. Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models. Oncogene. 2000;19:1065–1071.
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Iwatsuki A, Sugito N, et al. Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells. Mol Carcinog. 2018;57:579–589.
   PubMed Web of Science ®Google Scholar
• Wu G, Xing Z, Tran EJ, et al. DDX5 helicase resolves G-quadruplex and is involved in MYC gene transcriptional activation. Proc Natl Acad Sci U S A. 2019;116:20453–20461.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Khanin R, Carvajal RD, et al. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells. Mol Cancer Ther. 2014;13:2073–2080.
   PubMed Web of Science ®Google Scholar
• Boussemart L, Malka-Mahieu H, Girault I, et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014;513:105–109.
   PubMed Web of Science ®Google Scholar
• Cerezo M, Guemiri R, Druillennec S, et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018;24:1877–1886.
   PubMed Web of Science ®Google Scholar
• Phung B, Cieśla M, Sanna A, et al. The X-linked DDX3X RNA helicase dictates translation reprogramming and metastasis in melanoma. Cell Rep. 2019;27:3573–3586.e3577.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu W, Tao G, et al. Circular RNA circ-LRP6 facilitates Myc-driven tumorigenesis in esophageal squamous cell cancer. Bioengineered. 2020;11:932–938.
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.
   PubMed Web of Science ®Google Scholar
• Chana JS, Grover R, Tulley P, et al. The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma. Br J Plast Surg. 2002;55:623–627.
   PubMedGoogle Scholar
• Lin X, Sun R, Zhao X, et al. C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling. J Mol Med (Berl). 2017;95:53–67.
   PubMed Web of Science ®Google Scholar
• Mannava S, Grachtchouk V, Wheeler LJ, et al. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle. 2008;7:2392–2400.
   PubMed Web of Science ®Google Scholar
• Kraehn GM, Utikal J, Udart M, et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer. 2001;84:72–79.
   PubMed Web of Science ®Google Scholar
• D’Agnano I, Valentini A, Fornari C, et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels. Oncogene. 2001;20:2814–2825.
   PubMed Web of Science ®Google Scholar
• Tulley PN, Neale M, Jackson D, et al. The relation between c-myc expression and interferon sensitivity in uveal melanoma. Br J Ophthalmol. 2004;88:1563–1567.
   PubMed Web of Science ®Google Scholar
• Fico A, Alfano D, Valentino A, et al. c-Myc modulation: a key role in melanoma drug response. Cancer Biol Ther. 2015;16:1375–1386.
   PubMed Web of Science ®Google Scholar
• Bucci B, D’Agnano I, Amendola D, et al. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res. 2005;11:2756–2767.
   PubMed Web of Science ®Google Scholar
• Mahapatra L, Andruska N, Mao C, et al. IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl Oncol. 2017;10:818–827.
   PubMed Web of Science ®Google Scholar